文献速递血液净化与透析水电解质与酸碱遗传性与小管间质肾病

3岁以下维持性透析儿童使用西那卡塞的安全性与疗效

Safety and Efficacy of Cinacalcet in Children Aged Under 3 Years on Maintenance Dialysis.
PubMed 文献 · Kidney Int Rep · 2024-05-07

本研究纳入8个欧洲儿科中心的26例3岁以下透析患儿,中位起始年龄18个月,中位PTH为正常上限的11.6倍。西那卡塞治疗6、12个月及以后PTH分别降至4.3、2.0、1.6倍正常上限,7例出现10次低钙血症事件,3例出现性早熟临床征象。

要点

  • 西那卡塞可有效控制3岁以下透析患儿的严重继发性甲旁亢。
  • 治疗中需警惕低钙血症(7/26例)和性早熟(3/26例)等不良反应。
  • 需精细管理钙摄入(营养、补充及透析液)并监测内分泌变化。

核心结论

  • 西那卡塞可有效控制3岁以下透析儿童的严重继发性甲状旁腺功能亢进。

研究设计与样本

  • 多中心回顾性研究,纳入2009至2021年间8个欧洲儿科中心的26例3岁以下维持性透析患儿。

主要发现

  • 西那卡塞起始中位年龄为18(四分位距11-27)个月,起始时中位PTH为792(411-1397)pg/ml,相当于正常上限的11.6(5.9-19.8)倍。
  • 中位随访1.2(0.7-2.0)年,PTH在治疗6个月后降至正常上限的4.3(2.2-7.8)倍,12个月后降至2.0(1.0-5.3)倍,此后降至1.6(0.5-3.4)倍(对数转换PTH的P值分别为0.017、0.003和<0.0001)。
  • 26例患儿中7例发生10次低钙血症事件(血钙<2.10 mmol/l)。
  • 3例患儿出现性早熟的临床征象。
  • 口服钙摄入量在起始时为推荐营养摄入量的84%(66%-117%),治疗3个月时为100%(64%-142%),治疗12个月时降至78%(65%-102%)。

关键数值与推荐

  • 西那卡塞初始剂量为0.4(0.2-0.8)mg/kg/d,最大剂量为1.1(0.6-1.2)mg/kg/d。
  • 起始时中位血清钙为2.56(2.43-2.75)mmol/l,血清磷为1.47(1.16-1.71)mmol/l。
  • 起始时中位血清25-羟维生素D为70(60-89)nmol/l,3例患儿存在维生素D缺乏(<50 nmol/l)。

临床怎么用

  • 对3岁以下透析患儿可考虑使用西那卡塞控制严重继发性甲旁亢,但需密切监测血钙并精细调整钙摄入(包括营养、补充剂及透析液)。
  • 治疗期间应监测内分泌变化,警惕性早熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Secondary hyperparathyroidism (sHPT) is particularly severe in rapidly growing infants in dialysis. Although cinacalcet is effective and licensed in dialysis in children aged >3 years, its efficacy and safety for children aged <3 years is unknown. METHODS: We identified 26 children aged <3 years who were on dialysis and treated with cinacalcet between 2009 and 2021 in 8 European pediatric centers. RESULTS: Median (interquartile range) age at the start of cinacalcet was 18 (interquartile range: 11-27) months, serum parathyroid hormone (PTH) was 792 (411-1397) pg/ml, corresponding to 11.6 (5.9-19.8) times the upper limit of normal (ULN). Serum calcium was 2.56 (2.43-2.75) mmol/l, and serum phosphate 1.47 (1.16-1.71) mmol/l. Serum 25-OH vitamin D (25-OHD) was 70 (60-89) nmol/l, 3 children were vitamin D deficient (<50 nmol/l). The initial cinacalcet dose was 0.4 (0.2-0.8) mg/kg/d and the maximum dose was 1.1 (0.6-1.2) mg/kg/d. The median follow-up under cinacalcet was 1.2 (0.7-2.0) years. PTH decreased to 4.3 (2.2-7.8) times the ULN after 6 months, to 2.0 (1.0-5.3) times ULN after 12 months, and to 1.6 (0.5-3.4) times thereafter (P = 0.017/0.003/<0.0001, log-transformed PTH). Seven of the 26 infants developed 10 hypocalcemic episodes <2.10 mmol/l. Oral calcium intake was 84% (66%-117%) of recommended nutrient intake at start, 100% (64%-142%) at 3 months and declined to 78% (65%-102%) at 12 months of therapy. Three children developed clinical signs of precocious puberty. CONCLUSION: Cinacalcet efficiently controlled severe sHPT in children aged <3 years and was associated with hypocalcemic episodes (similar to what is observed in older children) and precious puberty, thereby mandating meticulous control of calcium (considering nutrition, supplementation, and dialysate) and endocrine changes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bernardor J, Flammier S, Zagozdzon I, et al. Safety and Efficacy of Cinacalcet in Children Aged Under 3 Years on Maintenance Dialysis. Kidney Int Rep. 2024. PMID: 39081774. doi:10.1016/j.ekir.2024.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。